Anticancer agent 264

• Description :

  Anticancer agent 264 (Compound 5w) is an anticancer agent that exhibits significant antiproliferative activity across tumor cell lines, with an IC50 range of 7.5-33.67 μM. Anticancer agent 264 significantly induces G2/M phase arrest in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. Anticancer agent 264 reduces the expression of key cell cycle proteins, including CDK1, CDK2, and Cyclin B1, in a dose-dependent manner, and shows strong binding affinity with inhibitor of differentiation (ID) proteins and DNA-binding proteins. Anticancer agent 264 can be used for research in the field of cancer-related diseases[1].

• UNSPSC :

  12352005

• Target :

  CDK; DNA/RNA Synthesis

• Related Pathways :

  Cell Cycle/DNA Damage

• Field of Research :

  Cancer

• Smiles :

  ClC1=C(NC(C2=NOC(CN3CCN(C4=C(C(F)=C(C(F)=C4F)F)F)CC3)=N2)=N1)C5=CC=C(C=C5)C

• Molecular Formula :

  C23H18ClF5N6O

• Molecular Weight :

  524.87

• References & Citations :

  [1]Nagineni D, et al. Imidazole-1,2,4-oxadiazole-piperazine hybrids as potent anticancer agents: Synthesis, biological evaluation and molecular docking. Bioorg Chem. 2025 Mar;156:108208.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK1; CDK2